Berger Montague Investigates Securities Claims for Skye Bioscience Investors After Class Action Filing

Berger Montague PC represented investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities during the Class Period in connection with a class action filed against Skye Bioscience, Inc. The filing alleges that, throughout the Class Period from November 4, 2024 through October 3, 2025, defendants failed to disclose that the efficacy of nimacimab, Skye’s lead product candidate, was lower than had been represented to investors and that, as a result, the drug’s clinical and commercial potential had been overstated. The complaint notes that on October 6, 2025 Skye issued a press release reporting topline data from its 26‑week Phase 2a CBeyond proof‑of‑concept study of nimacimab, disclosing that the primary endpoint—an 8% difference in weight loss versus placebo—had not been met. Following that disclosure, Skye’s stock declined $2.85 per share, or approximately 60%, to close at $1.90 on October 6, 2025. Skye Bioscience is a San Diego‑headquartered clinical‑stage biotechnology company developing treatments for obesity and metabolic diseases. Investors who purchased Skye securities during the Class Period may seek appointment as lead plaintiff no later than January 16, 2026. Berger Montague PC represented investors who purchased or otherwise acquired Skye Bioscience, Inc. securities during the Class Period with a team composed by: Andrew Abramowitz, Senior Counsel; Caitlin Adorni, Director of Portfolio & Institutional Client Monitoring Services.

Berger Montague Investigates Securities Claims for Skye Bioscience Investors After Class Action Filing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads